Form 4: Dyne Therapeutics CMO Sells Shares for Tax Obligations
Insider Transaction Report
Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, sold common stock totaling 4,425 shares to cover tax withholding obligations from RSU vesting.
Summary
- Douglas Kerr, Chief Medical Officer of Dyne Therapeutics, Inc., reported sales of common stock.
- On September 4, 2025, 3,552 shares were sold at a weighted average price of $13.27 per share, with prices ranging from $13.07 to $13.50.
- On September 5, 2025, an additional 873 shares were sold at a price of $13.41 per share.
- These sales were non-discretionary, executed automatically to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs).
- The RSUs were granted on September 3, 2024, and December 4, 2024.
- Following these transactions, Douglas Kerr directly beneficially owns 88,390 shares of common stock, which includes 74,625 unvested RSUs.
- The transactions were made pursuant to a Rule 10b5-1(c) plan.
Sentiment
Score: 5
Explanation: The transactions are routine, non-discretionary sales for tax purposes related to RSU vesting, executed under a pre-arranged 10b5-1 plan. They do not reflect a change in management's discretionary view of the company's prospects.
Positives
- The sales were non-discretionary, indicating a pre-planned event for tax purposes rather than a discretionary decision to sell by the officer.
- The transactions were executed under a Rule 10b5-1(c) plan, providing an affirmative defense against insider trading allegations.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- The filing details transactions by Douglas Kerr, Chief Medical Officer, who is considered a related party. The transactions involve the sale of company stock to cover tax obligations from RSU vesting.
Stakeholder Impact
- Shareholders: Minimal direct impact as these are routine, non-discretionary sales for tax purposes and do not signal a change in the officer's confidence in the company. The volume of shares sold is relatively small compared to the company's total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 2024-09-03 | Date of RSU grant for which tax withholding obligations were satisfied. |
| 2024-12-04 | Date of RSU grant for which tax withholding obligations were satisfied. |
| 2025-09-04 | Transaction date for the sale of 3,552 shares of common stock. |
| 2025-09-05 | Transaction date for the sale of 873 shares of common stock. |
| 2025-09-08 | Signature date of the Form 4 filing. |
Keywords
Dyne Therapeutics, DYN, Douglas Kerr, Chief Medical Officer, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.